Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supreme Court To Hear Arguments On Scope Of “Bolar Amendment” April 20

This article was originally published in The Pink Sheet Daily

Executive Summary

Pharma companies and BIO ask the high court not to create a “bright line” test for determining what types of research are protected. The appeals court decision in Merck KGaA v. Integra found that the Waxman/Hatch “safe harbor” protection from patent infringement claims did not extend to preclinical research.

You may also be interested in...



“Bolar Amendment” Provides Broad Protection For Drug Research, Supreme Court Says

The Waxman/Hatch safe harbor from patent infringement claims encompasses preclinical research on compounds that are not ultimately the subject of an FDA submission, the Supreme Court unanimously rules in the Merck v. Integra case.

“Bolar Amendment” Provides Broad Protection For Drug Research, Supreme Court Says

The Waxman/Hatch safe harbor from patent infringement claims encompasses preclinical research on compounds that are not ultimately the subject of an FDA submission, the Supreme Court unanimously rules in the Merck v. Integra case.

Supreme Court Questions Role Of Preclinical Efficacy Data In IND Process

During oral arguments in the Merck KGaA v. Integra case, several justices suggest that preclinical efficacy data are a key consideration during the IND process and may warrant “safe harbor” protection from patent infringement claims under the “Bolar Amendment.”

Topics

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel